Teva Pharmaceuticals Usa, Inc.

Teva Pharmaceuticals Usa, Inc., a foreign-owned pharmaceutical manufacturer headquartered in Parsippany, New Jersey, supplies vaccines, specialty pharmaceuticals, and respiratory medications to federal healthcare agencies as a prime contractor competing in full-and-open procurements with no set-aside designations. The company is a subsidiary of Israeli-based Teva Pharmaceutical Industries Ltd. and maintains a named subsidiary, Anda, Inc.

Teva's federal footprint centers on Adenovirus Type 4 vaccine delivery to the Department of Defense's Medical Supply Chain through the Defense Logistics Agency Troop Support Medical, with 559 delivery orders under the primary Indefinite Delivery Contract (SPE2DP20D0002) accounting for $665.9 million in combined potential value. Recent work includes hundreds of firm-fixed-price delivery orders ranging from $152 thousand to $5.3 million for Adenovirus Type 4 vaccine, each completing within one to two weeks of award, supporting critical military immunization programs. Beyond vaccines, Teva holds three major indefinite-delivery contracts: a $64.4 million single-award IDC with the Department of Veterans Affairs National Acquisition Center (awarded August 5, 2023, extending through August 4, 2027) for glatiramer acetate injections in 20mg/mL and 40mg/mL dosage strengths for multiple sclerosis treatment across VA, DoD, Bureau of Prisons, and Indian Health Service; a $5.69 million single-award IDC with DLA Troop Support Medical (awarded August 31, 2022, extending through August 30, 2027) establishing Teva as national prime vendor for Levalbuterol HCL Solution respiratory treatment; and a $25 billion multiple-award Federal Supply Schedule contract (FSS-61-IB, Drugs, Pharmaceuticals & Hematology Related Products) awarded June 1, 2026, through May 31, 2031, enabling federal agencies to order against Teva's price list without separate competition.

Customer concentration is dominated by defense and VA healthcare programs. The top five customers by award count account for 76 percent of awards, led by Defense Logistics Agency Troop Support Medical (559 awards, $665.9 million), Defense Logistics Agency (100 awards), Department of Veterans Affairs (37 awards), Department of Health and Human Services Indian Health Service (24 awards, $175 thousand), and Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 (18 awards). By potential value, the ranking inverts sharply: Veterans Integrated Service Network 12 anchors 97 percent of combined potential value at $28.9 billion across just 18 awards, reflecting the massive ceiling on the GSA Schedule contract. Department of Veterans Affairs National Acquisition Center contributes $2.09 billion across 6 awards (the glatiramer acetate IDC and related orders), while DLA Troop Support Medical's 559 vaccine delivery orders represent $665.9 million.

Activity has been consistent at 68 to 91 awards per year over the past five years, with 976 total prime awards in the source data and $32.76 billion combined potential value. Place of performance for all work is Teva's Parsippany, New Jersey facility. Teva operates exclusively as a prime contractor; the source shows zero sub-awards. The company competes in unrestricted procurements as a large business, with no small-business set-asides across its federal portfolio. NAICS coding reflects pharmaceutical preparation manufacturing (716 awards) and medicinal and botanical manufacturing (61 awards); PSC codes are dominated by Drugs and Biologicals (913 awards). Teva's federal strategy centers on supply-chain criticality—serving as sole-source or national prime vendor for essential medical products to multiple federal health agencies simultaneously, leveraging long-term IDCs and high-volume delivery-order vehicles to ensure reliable access to vaccines and specialty pharmaceuticals across DoD, VA, Bureau of Prisons, and Indian Health Service.